Juno Therapeutics, Inc. announced today that clinical data from its most advanced chimeric antigen receptor product candidates, JCAR017, JCAR015 and JCAR014, demonstrated encouraging evidence of clinical responses in acute lymphoblastic leukemia and non-Hodgkin's lymphoma . Clinical results were presented in oral and poster presentations at the 56th American Society of Hematology Annual Meeting in San Francisco, California.
http://ift.tt/1D1p9Ar
http://ift.tt/1D1p9Ar
No comments:
Post a Comment